CY1114550T1 - USE OF PARASITIC BIOLOGICAL FACTORS TO PREVENT AND CONTROL INFLAMMATIC INTELLIGENCE - Google Patents
USE OF PARASITIC BIOLOGICAL FACTORS TO PREVENT AND CONTROL INFLAMMATIC INTELLIGENCEInfo
- Publication number
- CY1114550T1 CY1114550T1 CY20131100825T CY131100825T CY1114550T1 CY 1114550 T1 CY1114550 T1 CY 1114550T1 CY 20131100825 T CY20131100825 T CY 20131100825T CY 131100825 T CY131100825 T CY 131100825T CY 1114550 T1 CY1114550 T1 CY 1114550T1
- Authority
- CY
- Cyprus
- Prior art keywords
- immune response
- overactive immune
- inflammatic
- intelligence
- prevent
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η εφεύρεση σχετίζεται με μέθοδο αγωγής έναντι υπερβολικής απόκρισης του ανοσοποιητικού συστήματος συμπεριλαμβανομένης μίας παρεκκλίνουσας/ενισχυμένης απόκρισης των Τh1 χορηγώντας ελμινθικό παρασιτικό παρασκεύασμα σε ποσό επαρκές ώστε να μειωθεί η υπερβολική απόκριση του ανοσοποιητικού σε ένα άτομο. Αυτή η εφεύρεση γενικώς προσανατολίζεται σε αυτοάνοσες ασθένειες οι οποίες ενέχουν υπερβολική απόκριση του ανοσοποιητικού ή παρεκκλίνουσα/ενισχυμένη απόκριση των Τh1. Πιο συγκεκριμένα, η παρούσα εφεύρεση προσανατολίζεται στην αγωγή έναντι της νόσου του Crohn και έναντι της ελκώδους κολίτιδας, αμφότερων γνωστών ως ΦΝΕ. Αν και η παρούσα εφεύρεση φέρνει στο προσκήνιο συγκεκριμένες πληροφορίες σχετικά με την αγωγή έναντι των ΦΝΕ, η παράθεση δεν είναι κατ' οποιονδήποτε τρόπο περιοριστική. Επιπροσθέτως, η ρευματοειδής αρθρίτιδα, ο σακχαρώδης διαβήτης τύπου 1, ο ερυθηματώδης λύκος, η σαρκοείδωση και η σκλήρυνση κατά πλάκας μπορούν να αντιμετωπιστούν υπό αγωγή μέσω των μεθόδων και συνθέσεων όπως έρχονται στο προσκήνιο στο παρόν.The invention relates to a method of treating an overactive immune response including a derogatory / enhanced response of Th1 by administering an elminant parasitic preparation in an amount sufficient to reduce an overactive immune response in a subject. This invention is generally directed to autoimmune diseases which involve an overactive immune response or a deviating / enhanced response to Th1. More particularly, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as FNE. Although the present invention brings to the fore specific information about treatment against VNS, the quotation is not in any way limiting. In addition, rheumatoid arthritis, type 1 diabetes mellitus, erythematosus lupus, sarcoidosis and multiple sclerosis can be treated by the methods and compositions as presented herein.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7014797A | 1997-12-31 | 1997-12-31 | |
| EP06021312.1A EP1749534B1 (en) | 1997-12-31 | 1998-12-11 | Use of parasitic biological agents from for prevention and control of inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114550T1 true CY1114550T1 (en) | 2016-10-05 |
Family
ID=58448795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100825T CY1114550T1 (en) | 1997-12-31 | 2013-09-20 | USE OF PARASITIC BIOLOGICAL FACTORS TO PREVENT AND CONTROL INFLAMMATIC INTELLIGENCE |
Country Status (1)
| Country | Link |
|---|---|
| CY (1) | CY1114550T1 (en) |
-
2013
- 2013-09-20 CY CY20131100825T patent/CY1114550T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1100745A1 (en) | Use of parasitic biological agents from for prevention and control of inflammatory bowel disease | |
| NO982062D0 (en) | Humanized antibodies to human gp39, compositions containing them, and therapeutic use thereof | |
| CY1114445T1 (en) | 2,4-Pyrimidinodiamine Compounds For Use In Therapeutic Treatment Or Prevention Of Autoimmune Diseases | |
| ATE510562T1 (en) | ANTI-AILIM ANTIBODIES FOR THE TREATMENT OF CROHN'S | |
| DE69533040D1 (en) | MEDICINES FOR PREVENTING OR TREATING VASCULAR HEMORRHAGIA | |
| TW264480B (en) | ||
| ATE76294T1 (en) | GALANTHAMINE OR ITS ANALOGUES FOR THE TREATMENT OF ALZHEIMER'S DISEASE. | |
| BR0307788A (en) | reduction method and treatment of uv-b-induced immunosuppression | |
| DE69721006D1 (en) | USE OF THE OWN MODIFIED OWN BLOOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| MX9207032A (en) | THERAPEUTIC METHOD | |
| EP0552296A4 (en) | Mouse monoclonal antibodies | |
| DE69418183D1 (en) | IMMUNOTHERAPEUTIC PREPARATION | |
| NO952336L (en) | Insulin analogues | |
| NO920331D0 (en) | BIOLOGICAL PREPARATION AND USE THEREOF | |
| ATE81467T1 (en) | IMMUNOSUPPRESSION IN IMMUNOTOXIN-BASED TREATMENT OF HUMANS. | |
| DE60042941D1 (en) | USE OF ANTI-CD3 MONOCLONAL ANTIBODIES AND IL-5 FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| CY1114550T1 (en) | USE OF PARASITIC BIOLOGICAL FACTORS TO PREVENT AND CONTROL INFLAMMATIC INTELLIGENCE | |
| DE3884440T2 (en) | Method and agent for the preventive treatment of autoimmune diseases. | |
| DE69429521T2 (en) | COMPOSITION AND METHOD FOR STIMULATING REPRODUCTIVE PERFORMANCE | |
| DE69829995D1 (en) | MULTIVALENT RECOMBINANT ANTIBODIES FOR THE TREATMENT OF HRV INFECTIONS | |
| NO20034453D0 (en) | Use of CD25-binding molecules in steroid-resistant patients | |
| DE69821970D1 (en) | Use of CITICOLINE FOR TREATING MULTIPLE Sclerosis | |
| ATE419370T1 (en) | LENTIVIRAL VECTORS FOR TREATING PAIN | |
| GR3001850T3 (en) | Expellants of phytopathogenic microbes | |
| DE60303296D1 (en) | USE OF (3- (2-ETHYLPHENYL) -5-METHOXYPHENYL) -1H- (1,2,4) -TRIAZOL FOR THE TREATMENT OF AUTOIMMUNE DISEASES |